CONTURA A/S — Regnskab

CVR 25057716

Seneste regnskabsperiode

2025 • 2025-01-01 • 2025-12-31 • entity • DKK • 311969554 • 185263644 • 63748304 • 68939582 • 655703980 • 199526949 • 128

Regnskabshistorik

2024 • 2024-01-01 • 2024-12-31 • entity • DKK • -1445705 • -7262568 • 24280154 • 284794429 • 130587367 • 1
2023 • 2023-01-01 • 2023-12-31 • entity • DKK • -1032615 • -2647944 • 14770792 • 241325915 • 105900571
2022 • 2022-01-01 • 2022-12-31 • entity • DKK • 3869747 • 1124633 • 5822589 • 206308064 • 72139779
2021 • 2021-01-01 • 2021-12-31 • entity • DKK • -17517307 • -20263954 • -3224092 • 193543150 • 66317189
2020 • 2020-01-01 • 2020-12-31 • entity • DKK • 101263 • 5185470 • 176514054 • 69541281
2019 • 2019-01-01 • 2019-12-31 • entity • DKK • 1034818 • 9076277 • 158724759 • 64355811
2018 • 2018-01-01 • 2018-12-31 • entity • DKK • 1046114 • 1046114 • 8024499 • 136709485 • 55279534 • 0
2017 • 2017-01-01 • 2017-12-31 • entity • DKK • 329000 • 329000 • 4483000 • 102612000 • 47256000 • 0

Højdepunkter fra årsrapporten

primary activities • Business reviewContura A/S, the Company, is the holding company for Contura International A/S and Contura Properties A/S, together referred to as the Group. Contura Properties owns the manufacturing building and Contura International A/S operates the manufacturing of the Group’s products. Contura A/S holds all patents and trademarks associated with the Group’s products. These are then licensed through Contura International A/S to related companies outside of the Group. The Group develops and manufactures innovative medical products for use within human orthopedics, urology and bowel, and animal health using its unique polyacrylamide hydrogel technology. • entity
development in activities and financial affairs • Financial review The Group's income statement for the year ended 31 December 2025 shows a profit of DKK 68.939.582, and the balance sheet at 31 December 2025 shows equity of DKK 199.526.949. • entity
expected development • Expected development of the Company and the Group, including specific prerequisites and uncertaintiesIn 2026, an increase in revenue and gross profit similar to that of 2025 is expected. The Group continues to expect a positive cash flow in 2026. Special risks - operational risks and financial risks: The Group continuously works to identify risks that may affect the Group's future growth, activities, financial position, and results, and seeks to counteract and limit as much as possible the risks that the Group can influence through its actions. Operational risks: The Group's most significant operational risks are related to Manufacturing and Regulatory issues. (1) Manufacturing; Notwithstanding contractual terms to the contrary, contract manufacturers and suppliers used by the Group could cease supply at short notice, resulting in delays in manufacturing, product sales and increased costs. Manufacturing development programmes may encounter delays due to technical problems, for instance in scaling-up manufacturing processes so that commercial quantities of products can be made or growth in sales can be achieved. Third-party manufacturers are subject to regulatory requirements, which may impact on the Group’s development and commercialisation of its products. The Group seeks to mitigate its manufacturing risk, where it is commercially reasonable to do so, by purchasing manufactured goods from more than one source of supply. (2) Regulatory; Regulatory bodies around the world have different requirements for the approval of healthcare products. This may result in restriction of indication, denial of approval, or demands for additional data, particularly in those territories in which approval has not yet been received by the Group. After product approval, safety or efficacy issues may emerge during post-marketing surveillance, which may result in withdrawal or restriction of the product licence. This may have an impact on the growth plans of the Group. The Group seeks to mitigate its regulatory risk by employing expert staff and third party regulatory advisers. Currency risks: The Group's foreign operations are affected by exchange rate fluctuations, as revenue is primarily generated in foreign currency, but a large part of the costs, including salaries, is incurred in Danish kroner. It is the Group’s policy not to hedge currency risks as a general rule, but this is assessed on a case-by-case basis and from currency to currency. Liquidity risks: It is the Group's policy to have credit facilities that are sufficient for the planned activities of the Group. • entity
result compared with expectations • Profit/loss for the year relative to the expectations most recently expressedPerformance exceeded the expectations set out in the 2024 annual report, driven largely by increased demand for the Group's human orthopedics, urology and bowel, and animal health products. Management considers the year's results satisfactory. • entity
recognition measurement uncertainty • Recognition and measurement uncertaintiesThe recognition and measurement of items in the annual report for the Group are not associated with any material uncertainties. Management make provisions for doubtful debtors based on the risk of loss due to customer's inability to pay, and provisions for obsolescent stock. Raw materials, work in progress, and finished goods are reviewed on a monthly basis, and scrap and obsolescent stock is written-off. • entity
unusual matters • The Group's financial position at 31 December 2025 and the results of its operations and cash flows for the financial year ended 31 December 2025 are not affected by any unusual matters.For the purpose of ensuring correct classification in the annual financial statements the following classifications have been updated and the comparative figures have been corrected as well. This relates to the following: 1. Other staff costs amounting to DKK 3.949 thousand, were classified as other external costs rather than staff costs. The change in classification has had no impact on the profit for the year, total assets or equity for 2024. 2. Software corresponding to DKK 99 thousand had previously been presented as tangible assets. This has been corrected to intangible assets. The change in classification has had no impact on the profit for the year, total assets or equity for 2024. 3. Development projects regarding software had been classified as tangible assets in the previous year. This has been corrected to intangible assets. The change in classification had no impact on the profit for the year, total assets or equity for 2024. However, the reserve for development costs of DKK 4.885 thousand was not recognised in 2024. This reserve has been updated in 2025 to DKK 47.174 thousand. • entity
subsequent events • Significant events occurring after the end of the financial yearNo events have occurred after the balance sheet date which could significantly affect the Group's financial position. • entity
contingent liabilities • The Company serves as an administration company in Danish joint taxation arrangement. According to the joint taxation provisions of the Danish Corporation Tax Act, the Company is therefore liable for income taxes etc. for the jointly taxed entities, and also for obligations, if any, relating to the withholding of tax on interest, royalties and dividends for the entities. The Company has unlimited pledge towards Contura International A/S.Rent and lease liabilitiesThe Group has unrecognised rental and lease commitments regarding cars and rent amounting to DKK 1.381 thousand with remaining terms of 5-51 months. • entity
mortgages collateral • The Company has entered into a floating charge over certain of its assets in the amount of DKK 5.000 thousand to secure the borrowings of the Company and of its subsidiary undertakings.The Group has entered into a floating charge over certain of its assets in the amount of DKK 20.000 thousand to secure the borrowings of the Group.Land and buildings at a carrying amount of DKK 220.885.009 have been provided as security for mortgage debt totalling DKK 7.717.243. • entity